CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE Drug Patent Profile

Which patents cover Calcipotriene And Bethamethasone Dipropionate, and when can generic versions of Calcipotriene And Bethamethasone Dipropionate launch?

Calcipotriene And Bethamethasone Dipropionate is a drug marketed by Padagis Israel and is included in one NDA.

The generic ingredient in CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE is betamethasone dipropionate; calcipotriene. There is one drug master file entry for this compound. Eight suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate; calcipotriene profile page.

Summary for CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE

US Patents:	0
Applicants:	1
NDAs:	1
DailyMed Link:	CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE at DailyMed

US Patents and Regulatory Information for CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Padagis Israel	CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE	betamethasone dipropionate; calcipotriene	SUSPENSION;TOPICAL	212367-001	Sep 11, 2020		DISCN	No	No

Calcipotriene and Betamethasone Dipropionate Market Dynamics, Patent Status, and Financial Trajectory

Last updated: August 7, 2026

Calcipotriene and betamethasone dipropionate is a mature topical fixed-dose combination used primarily for plaque psoriasis. The original branded products, Taclonex and Enstilar, face generic competition, payer pressure, and limited patent-based protection outside specific formulations. Market value is shifting from premium branded products toward generic ointments, suspensions, creams, and lower-cost dispensing channels. Public companies do not generally report product-level revenue for this combination, so financial analysis relies on product status, prescription mix, pricing, competitive entry, and company disclosures.

What is calcipotriene and betamethasone dipropionate?

Calcipotriene and betamethasone dipropionate combines a vitamin D analog with a topical corticosteroid.

Component	Pharmacologic role
Calcipotriene, also called calcipotriol outside the U.S.	Reduces abnormal keratinocyte proliferation and differentiation
Betamethasone dipropionate	Provides anti-inflammatory, antipruritic, and vasoconstrictive activity
Combination rationale	Targets separate biological mechanisms in plaque psoriasis

The combination is approved in multiple topical dosage forms:

• Ointment
• Topical suspension
• Aerosol foam
• Cream

The products are generally used for plaque psoriasis in adults and, depending on the formulation and label, in pediatric populations. Treatment duration, body-surface-area restrictions, and scalp or intertriginous-use limitations vary by product label. FDA labeling warns about corticosteroid-related risks, including hypothalamic-pituitary-adrenal-axis suppression, hyperglycemia, skin atrophy, and hypercalcemia associated with excessive exposure. [1-4]

Which branded drugs contain calcipotriene and betamethasone dipropionate?

The principal U.S. brands are Taclonex, Enstilar, and Wynzora.

Brand	Dosage form	U.S. sponsor or commercial owner	FDA approval
Taclonex	Ointment	Leo Pharma	2006
Taclonex	Topical suspension	Leo Pharma	2008
Enstilar	Aerosol foam	Leo Pharma	2015
Wynzora	Cream	MC2 Therapeutics	2020

Taclonex ointment and suspension were the first major U.S. branded products in the class. Enstilar introduced a foam delivery system intended to improve application and patient acceptance. Wynzora uses PAD Technology, a cream platform designed to deliver the two active ingredients in a formulation with different handling and cosmetic characteristics from ointment or foam. [1-4]

The product portfolio has therefore moved from a single fixed-dose combination into a formulation-led market. Clinical efficacy is important, but vehicle, ease of application, scalp usability, messiness, dispensing format, insurance coverage, and pharmacy substitution increasingly determine commercial performance.

When did calcipotriene and betamethasone dipropionate lose exclusivity?

The combination lost meaningful market exclusivity in stages rather than on one date.

Period	Market event	Commercial effect
2006-2008	Taclonex ointment and suspension approvals	Leo Pharma established the branded combination
2015	Enstilar foam approval	Premium differentiated formulation expanded the franchise
2019 onward	Generic approvals for certain topical presentations	Price pressure increased in mature dosage forms
2020	Wynzora cream approval	New branded formulation entered an already competitive category
2020s	Wider generic and payer substitution	Volume shifted toward lower-cost products

The relevant loss-of-exclusivity date depends on the dosage form and patent listing, not simply on the original approval date. A compound-level patent position is materially different from a formulation patent position. The active ingredients are old and widely used individually. Commercial protection has therefore depended on combination claims, vehicle technology, manufacturing processes, and formulation-specific patents.

What patents protect calcipotriene and betamethasone dipropionate?

Patent protection has historically centered on five categories:

1. The fixed-dose combination.
2. Specific ratios or concentration ranges.
3. Ointment and suspension compositions.
4. Foam delivery systems.
5. Cream formulations and manufacturing processes.

Taclonex was approved with calcipotriene 0.005% and betamethasone dipropionate 0.064%, equivalent to 0.05% betamethasone. Enstilar uses the same active-ingredient strengths in an aerosol foam. Wynzora uses the same nominal strengths in a cream formulation. [1-4]

The most commercially relevant patent question is whether a patent covers the active ingredients themselves or only a particular formulation. A formulation patent may block an identical generic product while leaving room for alternative dosage forms. This distinction explains why generic ointment competition can coexist with branded foam or cream sales.

What is the Orange Book status of Taclonex and Enstilar?

FDA Orange Book listings identify patents and regulatory exclusivities associated with approved products. Orange Book status must be reviewed by dosage form and NDA because Taclonex ointment, Taclonex suspension, Enstilar foam, and Wynzora cream have separate approval histories and potentially separate patent estates. [5]

The commercial implications are:

• Expired or removed listings do not necessarily eliminate all formulation or method-of-use rights.
• An Orange Book-listed patent can support a Paragraph IV notice and litigation under the Hatch-Waxman framework.
• A patent that is not listed in the Orange Book may still be enforceable, but it does not generate the same ANDA notice and automatic-stay mechanics.
• Patent-term adjustment, patent-term extension, pediatric exclusivity, and delisting can change effective dates.

A definitive current expiration analysis requires checking the live Orange Book entries, patent records, and any associated litigation docket. Product-level revenue and patent-level blocking power cannot be inferred from the approval date alone.

How many patents cover calcipotriene and betamethasone dipropionate?

There is no single economically meaningful patent count for the combination. The count changes based on:

• U.S. versus international coverage
• Brand product versus active ingredient
• Formulation versus method of use
• Granted patents versus pending applications
• Live patents versus expired patents
• Orange Book-listed patents versus non-listed patents
• Patent family members versus distinct inventions

A portfolio can contain multiple family members in the United States, Europe, Canada, Japan, and other markets while protecting one underlying formulation concept. Conversely, one active U.S. patent can be more commercially important than several expired family members.

The strongest remaining barriers typically involve differentiated vehicles, aerosol packaging, solvent systems, particle-size controls, stability, and manufacturing processes. These rights may complicate a generic launch even where the active ingredients are no longer novel.

What generic entry risks exist for calcipotriene and betamethasone dipropionate?

Generic competition is the central market risk for the mature ointment and suspension segments.

ANDA and Paragraph IV exposure

A generic applicant can file an ANDA with:

• Paragraph I certification, where no patent is listed
• Paragraph II certification, where the patent has expired
• Paragraph III certification, where the applicant agrees to wait until expiration
• Paragraph IV certification, where the applicant asserts that the patent is invalid, unenforceable, or not infringed

A Paragraph IV notice can trigger patent litigation and a potential 30-month stay of approval under the Hatch-Waxman statute. The commercial effect depends on the patent being challenged, the formulation targeted, the timing of the ANDA, and whether the generic applicant obtains first-filer status. [6]

For this drug class, the risk is presentation-specific:

Target	Generic risk	Main defense
Ointment	High	Formulation, method-of-use, or manufacturing patents
Topical suspension	High to moderate	Suspension stability and formulation claims
Foam	Moderate	Aerosol composition, packaging, and delivery patents
Cream	Moderate	Vehicle and delivery technology patents
New combination delivery systems	Lower initially	Active formulation and process patents

A generic ointment does not automatically establish substitutability for Enstilar foam or Wynzora cream. FDA-rated therapeutic equivalence and state substitution rules are dosage-form specific.

What is the FDA regulatory status?

The combination is an approved small-molecule topical drug, not a biologic. Biosimilar approval is therefore not relevant. Competitive products use the ANDA pathway when they meet the applicable requirements for generic equivalence, while new or materially differentiated formulations may require a 505(b)(2) application or a full NDA.

The regulatory routes are:

Regulatory pathway	Typical use in this market
ANDA	Generic version of an approved topical product
505(b)(2) NDA	New vehicle, delivery system, or reliance on prior findings
505(b)(1) NDA	New product requiring a complete independent application
Biosimilar pathway	Not applicable to this small-molecule combination

The key technical barriers for topical generics include comparative formulation characterization, drug release, permeation, particle size, rheology, physical stability, container-closure performance, and sometimes comparative clinical or pharmacodynamic evidence. FDA has issued product-specific guidance for certain topical products, and applicants must satisfy the reference-product requirements applicable to the targeted dosage form. [7]

How does Enstilar compare with Taclonex and Wynzora?

Attribute	Taclonex ointment/suspension	Enstilar foam	Wynzora cream
Sponsor	Leo Pharma	Leo Pharma	MC2 Therapeutics
Core differentiation	Established fixed-dose combination	Foam delivery	Cream delivery platform
Patient benefit sought	Efficacy and established use	Easier spreading and cosmetic acceptability	Less greasy application and differentiated vehicle
Generic exposure	High for mature presentations	Lower than ointment, subject to formulation patents	Increasing over time, depending on patent and regulatory status
Commercial strategy	Franchise retention and broad prescribing	Premium branded formulation	Differentiation through vehicle and patient experience

Foam and cream products can command a premium when payers reimburse them and patients value improved application. That premium is vulnerable to formulary restrictions, prior authorization, coupon dependence, and generic substitution in lower-cost presentations.

What is the market size and financial trajectory?

Publicly disclosed product-level revenue for calcipotriene and betamethasone dipropionate is limited. Leo Pharma is privately held and does not provide the level of audited product revenue detail commonly disclosed by large public pharmaceutical companies. MC2 Therapeutics also does not provide a broadly reported public revenue series for Wynzora.

The financial trajectory is nevertheless clear:

1. The original combination generated branded revenue during the period when Taclonex had limited direct generic competition.
2. Mature ointment and suspension products experienced price and volume pressure after generic entry.
3. Enstilar preserved premium economics through a differentiated foam presentation, but its addressable market remains exposed to payer controls and formulation-specific generic development.
4. Wynzora expanded branded competition rather than creating a monopoly position.
5. The market is likely to become increasingly bifurcated between low-price generics and premium branded delivery systems.

What drives revenue exposure?

The main revenue variables are:

• Number of treated plaque-psoriasis patients
• Duration of treatment
• Refill persistence
• Formulation mix
• Gross-to-net discounts
• Commercial insurance coverage
• Medicare and Medicaid exposure
• Prior authorization requirements
• Generic substitution
• Dermatology prescribing patterns
• Competition from biologics and nonsteroidal topicals

The combination competes with topical corticosteroid monotherapy, vitamin D analog monotherapy, tazarotene, roflumilast, tapinarof, and systemic or biologic therapies. Biologics compete for moderate-to-severe disease, while newer nonsteroidal topicals compete for patients who need chronic treatment or wish to avoid corticosteroid exposure.

How does the combination compare with newer psoriasis drugs?

Therapy category	Competitive position versus calcipotriene/betamethasone
Generic topical corticosteroids	Lower cost and broad familiarity
Calcipotriene monotherapy	Lower complexity but often lower perceived efficacy
Tapinarof	Nonsteroidal option with chronic-use positioning
Roflumilast	Nonsteroidal topical option with broader site-of-use potential
Biologics	Stronger efficacy for extensive disease but higher cost and administration burden
Phototherapy	Effective option with access and adherence limitations

Calcipotriene and betamethasone dipropionate remains commercially relevant because it combines established efficacy, topical administration, and relatively simple prescribing. Its limitations are chronic corticosteroid exposure, formulation inconvenience in some products, and substitution pressure.

Which companies are challenging the branded market?

The competitive field includes:

• Leo Pharma, through Taclonex and Enstilar
• MC2 Therapeutics, through Wynzora
• Generic manufacturers, including companies developing or marketing equivalent topical presentations
• Private-label and authorized-generic channels
• Manufacturers of competing nonsteroidal topical psoriasis therapies

Generic competition is more fragmented than the branded market. Manufacturers can compete through wholesale acquisition cost, pharmacy contracting, supply reliability, and dosage-form availability. A company with one approved generic presentation may still face limited commercial penetration if it lacks payer access or distribution scale.

What manufacturing and intellectual-property barriers remain?

Manufacturing complexity is higher for foam and cream products than for conventional ointments.

Important technical barriers include:

• Uniform distribution of both active ingredients
• Control of calcipotriene degradation
• Betamethasone dipropionate stability
• Particle-size distribution
• Emulsion or suspension stability
• Propellant compatibility for aerosol foam
• Container-closure integrity
• Spray performance
• In-use stability
• Scale-up consistency
• Microbiological control

These factors can support process and formulation patents even after the underlying combination has become commercially mature. They also raise the cost and timing risk of generic development.

What patent litigation and settlement issues affect the market?

Hatch-Waxman litigation is most relevant when an ANDA applicant files a Paragraph IV certification against an Orange Book-listed patent. A settlement can include a delayed generic entry date, licensing terms, authorized-generic provisions, or restrictions on launch. The economic value of a settlement depends on the remaining patent term, the probability of invalidity, the size of the branded franchise, and the number of other generic applicants.

There is no single settlement outcome that governs every calcipotriene and betamethasone dipropionate formulation. Litigation and settlement analysis must be conducted at the NDA, dosage-form, patent, and applicant levels using FDA records and federal court dockets. [5, 6]

How strong is the patent estate?

The patent estate is strongest for differentiated delivery systems and weakest for the basic active-ingredient combination.

Patent layer	Relative strength
Active ingredients individually	Low, because both are established molecules
Basic combination concept	Low to moderate, depending on claim scope and expiration
Ointment formulation	Moderate historically, now weakened by generic entry
Foam delivery system	Moderate to high while relevant patents remain live
Cream delivery technology	Moderate, with value tied to platform claims
Manufacturing and stability claims	Moderate, but dependent on enforceability and design-around options
Method-of-use claims	Variable and often narrower than composition claims

A strong estate must have claims that are difficult to design around, remain enforceable, and align with the product actually generating revenue. Broad expired combination patents have limited current value if commercially important formulations are protected only by narrower claims.

What are the likely generic launch scenarios?

Scenario 1: Continued generic erosion

Generic ointment and suspension products expand, reducing average selling prices and limiting branded growth. Taclonex revenue becomes concentrated in patients with brand preference, payer coverage, or prescriber loyalty.

Scenario 2: Branded formulation segmentation

Enstilar and Wynzora retain premium positioning because patients prefer foam or cream vehicles. The market divides into a low-cost generic segment and a formulation-led branded segment.

Scenario 3: Rapid foam substitution

A therapeutically equivalent foam reaches the market with favorable payer placement. Enstilar experiences sharper price erosion than expected, particularly if multiple manufacturers enter.

Scenario 4: Newer topical therapies take share

Tapinarof, roflumilast, or future nonsteroidal products gain use in chronic-treatment settings. The fixed combination remains used for short courses or rapid control but loses maintenance-treatment volume.

What is the geographic coverage?

The active ingredients are marketed internationally under different names, concentrations, regulatory classifications, and brand owners. Calcipotriol is the more common international name for calcipotriene. Patent and regulatory conclusions cannot be transferred directly from the United States to Europe, Canada, Japan, or emerging markets.

Geographic value depends on:

• Local patent term
• Supplementary protection certificates in Europe
• National generic approval rules
• Reference-product requirements
• Reimbursement systems
• Prescription versus pharmacy status
• Local manufacturing and supply arrangements

The United States remains the most important market for Orange Book and Paragraph IV analysis. European commercial value is more dependent on national reimbursement, tendering, and generic substitution than on a single centralized exclusivity date.

Key Takeaways

• Calcipotriene and betamethasone dipropionate is a mature topical psoriasis combination with multiple branded dosage forms.
• Taclonex established the market; Enstilar and Wynzora rely on differentiated delivery systems.
• Generic risk is high for ointment and suspension products and more formulation-dependent for foam and cream products.
• The product is a small molecule, so biosimilar risk does not apply.
• Current commercial protection depends more on formulation, delivery, manufacturing, and method-of-use patents than on active-ingredient novelty.
• Public product-level revenue data is limited because the principal branded owners are private or do not separately report the franchise.
• Financial performance is likely to remain under pressure in generic presentations while premium vehicles retain selective value.
• Orange Book listings, patent expiration dates, ANDA certifications, and litigation must be analyzed separately for each dosage form.
• The main long-term competitive threats are generic substitution, payer restrictions, and newer nonsteroidal topical therapies.

FAQs

Is calcipotriene and betamethasone dipropionate still patent protected?

Some formulation, delivery-system, manufacturing, or method-of-use patents may remain relevant by product and jurisdiction. The basic combination is commercially mature, and patent protection should be assessed at the dosage-form level.

Is Enstilar available as a generic?

Generic availability depends on the jurisdiction, dosage form, FDA approval status, and applicable Orange Book patents. Generic ointment or suspension approval does not establish that a foam is therapeutically substitutable.

Is Wynzora a generic version of Taclonex?

No. Wynzora is a separately developed cream formulation. It contains the same active ingredients but uses a distinct delivery platform and has its own FDA approval history.

Can calcipotriene and betamethasone dipropionate be substituted automatically?

Automatic substitution depends on FDA therapeutic-equivalence ratings, state pharmacy law, and the specific dosage form. Ointment, suspension, foam, and cream products should not be treated as interchangeable solely because they contain the same active ingredients.

Do biologics threaten the combination’s market?

Biologics compete primarily in moderate-to-severe psoriasis and can reduce demand among patients who escalate beyond topical treatment. The combination remains relevant in localized disease and as an initial or adjunctive topical therapy.

References

1. U.S. Food and Drug Administration. (2023). Taclonex ointment prescribing information. Drugs@FDA.
2. U.S. Food and Drug Administration. (2023). Taclonex topical suspension prescribing information. Drugs@FDA.
3. U.S. Food and Drug Administration. (2023). Enstilar aerosol foam prescribing information. Drugs@FDA.
4. U.S. Food and Drug Administration. (2023). Wynzora cream prescribing information. Drugs@FDA.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
6. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.
7. U.S. Food and Drug Administration. (2022). Product-specific guidances for generic drug development. FDA.